Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733289 | 1.00 | POLB (0.43) | POLBLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL12151916 | 1.00 | POLB (0.43) | POLBLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL12151876 | 0.91 | POLB (0.41) | POLBLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL14883422 | 0.90 | POLB (0.45) | POLBLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL12151879 | 0.90 | POLB (0.45) | POLBLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL12151979 | 0.88 | POLB (0.43) | POLBLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL12151927 | 0.86 | POLB (0.42) | POLBLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL12151951 | 0.86 | POLB (0.42) | POLBLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL14122623 | 0.85 | POLB (0.41) | POLBLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL4247829 | 0.85 | CYP2C9 (0.52) | POLBLMNAKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943221-B1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| US-7396830-B2 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-20070078141-A1 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078141-A1 | Piperazine amidines as antiviral agents | IDO1, IDO2, EIF2AK2 | POLB 1296/4885LMNA 4618/4885KDM4E 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.